The D-type cyclins (cyclins D1, D2, and D3) are components of the core cell cycle machinery in mammalian cells. Cyclin D3 gene is rearranged and the protein is overexpressed in several human lymphoid malignancies. In order to determine the function of cyclin D3 in development and oncogenesis, we generated and analyzed cyclin D3-deficient mice. We found that cyclin D3 Ϫ/Ϫ animals fail to undergo normal expansion of immature T lymphocytes and show greatly reduced susceptibility to T cell malignancies triggered by specific oncogenic pathways. The requirement for cyclin D3 also operates in human malignancies, as knock-down of cyclin D3 inhibited proliferation of acute lymphoblastic leukemias deriving from immature T lymphocytes. These studies point to cyclin D3 as a potential target for therapeutic intervention in specific human malignancies.
Introduction
transcription factors and allows induction of E2F-target genes that are required for the S phase entry (Dyson, 1998) . Hence, D-type cyclins are the ultimate recipients of mitogenic and onco-D cyclins lie at the interface between upstream oncogenic pathgenic signals. Three D cyclins (cyclins D1, D2, and D3) have ways and the retinoblastoma tumor suppressor protein. been described in mammalian cells. The three proteins are enConsistent with their growth-promoting functions, abnormal coded by separate genes, but they show substantial amino acid expression of D cyclins is believed to be a driving force in several similarity and are expressed in a highly overlapping fashion in human cancers. Indeed, chromosomal abnormalities involving all proliferating cells (Sherr and Roberts, 1999) .
cyclin D loci and overexpression of cyclin D protein were obOnce induced, D cyclins bind and activate their associated served in many malignancies. Cyclin D1 gene is rearranged or cyclin-dependent kinases CDK4 and CDK6 (Bates et al., 1994;  amplified and the protein is overexpressed in several human Kato et al., 1994; Meyerson and Harlow, 1994) . Cyclin D-CDK cancers such as breast carcinomas; squamous cell carcinomas complexes phosphorylate the retinoblastoma tumor suppressor of head and neck, esophagus, tongue, and larynx; carcinomas gene product, pRB, and pRB-related proteins p130 and p107 of uterine cervix; astrocytomas; non-small cell lung cancers; soft (Bates et al., 1994; Matsushime et al., 1992 Matsushime et al., , 1994 Meyerson and tissue sarcomas; mantle cell lymphomas; and others (Cheung et Harlow, 1994) . This phosphorylation cancels growth-inhibitory functions of pRB, leads to release or derepression of the E2F al., 2001; Fujii et al., 2001; Lammie et al., 1991 ; Withers et al., 1991; Bartkova et al., 1994; ; Weinstatwere fertile and appeared normal during the 1.5 year observation period (data not shown). However, we noticed that cyclin D3 Ϫ/Ϫ Saslow et al., 1995) . Cyclin D2 gene is amplified in human testicular tumors (Houldsworth et al., 1997; Sicinski et al., 1996) , mice displayed severely hypoplastic thymuses (Figure 2A ), which contained 7-fold fewer thymocytes than wild-type litwhile the protein is overexpressed in a wide range of B cell malignancies, such as B cell lymphocytic leukemias, lymphotermates ( Figure 2B ). To further investigate the defect seen in cyclin D3-deficient plasmacytic lymphomas (Delmer et al., 1995) , and chronic lymphocytic leukemias (Motokura and Arnold, 1993) .
thymuses, we analyzed T cell development in mutant animals. The great majority of T cells normally follow the developmental Cyclin D3 is the least studied of the D cyclins. It is expressed in nearly all proliferating cells, and it shows the most broad sequence
We found expression pattern of all three D-type cyclins (Bartkova et al., 1998) . Like other D cyclins, cyclin D3 is overexpressed in human that the percentage of double-negative cells was increased while the fraction of double-positive cells was decreased in the cancers (Buschges et al., 1999; Hedberg et al., 2002; Ito et al., 2001) . A potential role for cyclin D3 in the malignancies of the thymuses of cyclin D3 Ϫ/Ϫ animals, as compared with wild-type littermates ( Figure 2C ). When the absolute numbers of thymolymphoid system is suggested by the observations that cyclin D3 gene is rearranged in several neoplastic diseases deriving cytes in each fraction were calculated, we found that the total number of double-negative thymocytes was unchanged in mufrom this compartment, such as diffuse large B cell lymphomas or multiple myelomas (Filipits et al., 2002; Shaughnessy et al., tant animals, as compared with wild-type littermates, while the total number of double-positive cells was reduced over 12-fold 2001).
In the present study, we tested the role for cyclin D3 in ( Figure 2D ). development and in oncogenesis by generating cyclin D3-deficient mice. We found that cyclin D3 is critically required for the Impaired expansion of immature T lymphocytes The expansion of immature T lymphocytes within the thymus proliferative burst during development of immature T lymphocytes. Importantly, we found that cyclin D3 is essential for spenormally occurs at the double-negative stage (Muljo and Schlissel, 2000) . The double-negative population can be further subdicific oncogenic pathways operating in this compartment. Lastly, we demonstrate that this requirement for cyclin D3 also extends vided into four developmental stages, termed DN-1 to DN-4. Up to the DN-3, the proliferation of thymocytes is driven by the to human malignancies deriving from immature T lymphocytes. These studies raise a possibility of novel therapeutic approaches interleukins and c-kit (Di Santo et al., 2000) . A dramatic shift takes place at the DN-3 stage. At this point, immature lymphoin human T cell leukemias, centered on cyclin D3 inhibition.
cytes rearrange ␤ chains of their T cell receptor (TCR) and assemble the pre-TCR. The proliferation of thymocytes beResults comes cytokine independent, but it is driven instead by the pre-TCR (Fehling et al., 1995; Hoffman et al., 1996) . Signals Thymocyte defects in cyclin D3-deficient mice Cyclin D3 Ϫ/Ϫ mice were generated by gene targeting in ememanating from the pre-TCR drive expansion of the DN-4 and of "immature single-positive" (ISP) cells, which finally differentiate bryonal stem cells, using standard procedures (Figure 1 ). Cyclin D3-deficient animals were born with expected frequency; they into double-positive thymocytes and arrest their proliferation. double-negative (DN) and immature single-positive (ISP) thymocytes. The B: Total number of thymocytes in 4-to 6-week-old wild-type (n ϭ 11) and assembly of the pre-TCR is indicated. Shown are means of four independent cyclin D3 Ϫ/Ϫ (n ϭ 11) mice. Error bars denote SD.
experiments, each using pooled thymocytes from 5 mice, 4-6 weeks old. C: Examples of flow cytometric profiles of thymocytes from 5-week-old mice Error bars indicate SD. stained with anti-CD4 and anti-CD8 antibodies. The percentage of cells in B: Western blot analysis of thymocyte subsets from wild-type mice. Upper each quadrant is shown. and lower panels represent the same blot sequentially probed with antibod-D: Total number of CD4 Ϫ CD8 Ϫ double-negative (DN), CD4 ϩ CD8 ϩ doubleies against cyclin D3 and D2. DP denotes double-positive cells. positive (DP), CD4 ϩ , and CD8 ϩ thymocytes in 4-to 6-week-old wild-type C: Northern blot analysis of RNA prepared from indicated thymocyte subsets (n ϭ 8) and cyclin D3 Ϫ/Ϫ mice (n ϭ 9). Error bars denote SD.
from wild-type mice probed with a cyclin D3-specific probe. Ethidium-bromide-stained gel is shown below (loading control). D: Rag2 Ϫ/Ϫ mice were injected intraperitoneally with anti-CD3⑀ antibody. Thymocytes were harvested at 0, 12, and 18 hr after stimulation, and cyclin
To probe the proliferation rate of mutant thymocytes, we ulations, and we determined the percentage of proliferating cells immature T lymphocytes. In contrast, the pre-TCR-driven
Error bars indicate SE.
expansion of the DN-4 and ISP thymocytes was very reduced in cyclin D3-deficient mice ( Figure 3A) . Importantly, we determined that cyclin D3-deficient thymocytes expressed normal levels of TCR␤ and of other pre-TCR components (data not shown).
To address this issue further, we quantified the expression Collectively, these observations suggest that cyclin D3 might of cyclin D3 protein in sorted double-negative populations of operate downstream of the pre-TCR in driving proliferation of wild-type mice, using Western blotting. We found that cyclin immature T lymphocytes, and that in the absence of cyclin D3, D3 was strongly induced at the DN-4 and the ISP stages, i.e., the normally assembled pre-TCR fails to drive expansion of following pre-TCR assembly ( Figure 3B , upper panel). In contrast, cyclin D2 expression was high at cytokine-dependent immature thymocytes. stages (DN-1 to DN-3) but was essentially absent once TCR␤ rearrangements took place ( Figure 3B , lower panel). No expression of cyclin D1 was detected in the thymocytes (data not shown).
Northern blot analyses revealed a strong induction of cyclin D3 mRNA at the DN-4 stage, consistent with increased protein levels ( Figure 3C ). These observations reinforced the notion that cyclin D3 might be a critical downstream target of the signaling pathways emanating from the pre-TCR.
We next took advantage of mice deficient in recombinaseactivating gene (Rag). The thymocytes of these animals are arrested at the DN-3 stage (Mombaerts et al., 1992; . This arrest can be overcome by administration of anti-CD3⑀ antibodies, which mimics the signaling from the pre-TCR (Levelt et al., 1993; Shinkai and Alt, 1994) . We injected Rag-2-deficient mice with anti-CD3⑀ and determined the expression of cyclin D3 following the stimulation. Administration of anti-CD3⑀ antibodies led to rapid induction of cyclin D3 (Figure 3D ). This finding further supports our hypothesis that cyclin D3 operates downstream of the pre-TCR.
We next crossed Rag-2-deficient mice with cyclin D3 Ϫ/Ϫ animals and we generated double-knockout Rag2 Ϫ/Ϫ /cyclin D3 Ϫ/Ϫ animals. These mice, along with Rag2 Ϫ/Ϫ mice, were injected with anti-CD3⑀ antibody, and we monitored the response. As expected, Rag2 Ϫ/Ϫ mice responded with rapid cyclin D3 induction followed by a proliferative burst that led to approximately 60-fold increase in thymocyte numbers. In contrast, thymocyte expansion was virtually absent in Rag2 Ϫ/Ϫ mice lacking cyclin D3 ( Figure 3E ). This result further confirms that cyclin D3 is critically required for pre-TCR-driven expansion of immature thymocytes.
Cyclin D3 operates downstream of proto-oncogene p56
LCK kinase Levelt et al., 1995; Molina et al., 1992;  (LCK). Blots were probed with a cyclin D3-specific probe and were reprobed Mombaerts et al., 1994) . We noted that the developmental abwith glyceraldehyde-3-phosphate dehydrogenase cDNA (loading control). C: Cyclin D3 levels in p56 LCK -overexpressing thymic lymphoma cell line normalities in thymuses of cyclin D3-deficient mice bear strong
LGF2046. Cells were treated overnight with PP1, and inhibitor of p56 LCK . The resemblance to the phenotype of mice lacking p56 LCK (Levelt et inhibitor was then washed off and the levels of cyclin D3 were followed by al., 1995; Molina et al., 1992) . Hence, we hypothesized that contrast, this induction was essentially absent in mice lacking p56 LCK ( Figure 4A ). Hence, genetic ablation of p56 LCK abolished the induction of cyclin D3 after the pre-TCR formation, suggesting that the induction of cyclin D3 is controlled via p56 LCK -together with a cyclin D3-promoter-reporter construct resulted dependent pathway.
in over 3-fold induction of the cyclin D3 promoter (data not To further explore this notion, we compared cyclin D3 mRNA shown). and protein levels in the p56 LCK -deficient Jurkat T cell leukemia Lastly, we tested the connection between p56 LCK and cyclin D3 using two p56 LCK -transformed thymoblast cell lines, LGF2046 cell line, J.CaM, and in J.CaM cells that we engineered to express activated p56 LCK . We found that ectopic expression of and LGF10442. These lines were derived from a thymic lymphoma arising in transgenic mice overexpressing activated activated p56 LCK led to strong upregulation of cyclin D3 ( Figure  4B ). These findings were further strengthened by our observap56 LCK in immature T cells (Abraham et al., 1991; Lin and Abraham, 1997 LCK activation, and followed cyclin D3 levels by Western blotting. We found that cyclin D3 was strongly induced as early as 2 hr after triggering the kinase activity of p56 LCK ( Figure 4C ), well before any changes in proliferative status of cells could be observed (data not shown), again pointing to a direct link between p56 LCK signaling and cyclin D3. Collectively, our results suggest that cyclin D3 represents a critical target of the preTCR→p56
LCK pathway operating within immature T cells.
Requirement for cyclin D3 in mouse T cell malignancies
The observed role for cyclin D3 in T cell development prompted us to investigate the requirement for cyclin D3 in oncogenesis of this cellular compartment. To address this issue, we utilized three mouse models of T cell malignances: two involving the pre-TCR→p56 LCK -dependent pathway and one pre-TCR-independent pathway. First, we crossed cyclin D3-deficient mice with mice overexpressing p56 LCK . These transgenic mice are highly prone to T cell tumors due to targeted overexpression of p56 LCK in immature thymocytes (Abraham et al., 1991) . As expected (Abraham et al., 1991) , cyclin D3 ϩ/ϩ /p56 LCK transgenic mice rapidly developed T cell malignancies and died starting at 7 weeks of age. In contrast, the incidence of tumors was delayed by 6-8 weeks in cyclin D3 Ϫ/Ϫ /p56 LCK mice and the survival time was nearly doubled ( Figure 4D ).
In order to understand a bypass mechanism that eventually allowed delayed tumor appearance in cyclin D3-deficient mice, we analyzed the expression pattern of D cyclins in tumors arising in wild-type and cyclin D3 Ϫ/Ϫ mice. Our analyses revealed that were of the same immunophenotype (CD4
Incidence of leukemia (presence of CD4 ϩ CD8 ϩ leukemic cells in the peripheral blood) is indicated; all cyclin D3 ϩ/ϩ mice died at 11-13 weeks and data not shown). We interpret these findings as an indication proliferation via cyclin D2.
B:
Upper panels: total, GFP-positive, and GFP-negative peripheral blood
We extended these analyses using another model of T cell lymphocytes were stained with antibodies against TCR␤ and analyzed by flow cytometry. Lower panels: peripheral blood lymphocytes were stained malignancy, namely leukemias induced by the activated, intra- leukemias (T-ALL) (Bellavia et al., 2000) . Importantly, it is well and p53 Ϫ/Ϫ /cyclin D3 Ϫ/Ϫ (n ϭ 10) mice.
established that Notch-driven leukemogenesis critically requires pre-TCR signaling, as mice lacking pre-TCR components are resistant to Notch-induced leukemias (Allman et al., 2001 ; Beltransduction ( Figure 5A ). Peripheral blood leukemias persisted lavia et al., 2002). In our experimental approach, we collected until 11-13 weeks, when all mice died due to presence of multibone marrows from wild-type and cyclin D3-deficient animals, ple T cell tumors. In striking contrast, mice reconstituted with sorted their hematopoietic progenitor cells (HPC), and infected Notch-expressing cyclin D3 Ϫ/Ϫ bone marrow remained leukethe HPC with retroviruses encoding Notch1 together with GFP mia-free throughout the entire observation period ( Figure 5A ). (Aster et al., 2000; Pui et al., 1999) . These infected cells were Importantly, we verified that the transduced cyclin D3 Ϫ/Ϫ injected into sublethally irradiated recipients. As expected (Aster bone marrow cells contributed to the T cell compartment in the et al., Pui et al., 1999) , infection of wild-type bone marrow recipient animals. Analyses of peripheral blood revealed that with activated Notch led to appearance of T-ALL leukemias GFP-positive (i.e., transduced by Notch-IC) cyclin D3 Ϫ/Ϫ cells (presence of CD4 ϩ CD8 ϩ double-positive T cells in the peripheral blood) in 100% of recipient mice 2 weeks after bone marrow give rise to mature peripheral CD4 ϩ CD8 Ϫ and CD4 Ϫ CD8 ϩ T lymphocytes. These peripheral T cells expressed surface TCR␤, an indication that normal pre-TCR selection took place ( Figure  5B ). In contrast, wild-type cells transduced with Notch-IC gave rise to double-positive leukemic cells ( Figure 5B ). Collectively, these results indicate that cyclin D3 is required for Notch oncogenic pathway that signals through pre-TCR, as well as for p56
LCK pathway that signals downstream of the pre-TCR.
We next asked whether a similar requirement for cyclin D3 operated in pre-TCR-independent T cell malignancies. We took advantage of p53-deficient mice that develop T cell tumors in a pre-TCR-independent fashion (Liao et al., 1998; Nacht and Jacks, 1998) . Importantly, these tumors involve malignant transformation of the very same T cell subsets (double-positive) as pre-TCR-dependent Notch-driven tumors (Liao et al., 1998; Nacht and Jacks, 1998; Pui et al., 1999) . We crossed cyclin D3 Ϫ/Ϫ mice with p53-deficient animals and generated cyclin D3 Ϫ/Ϫ p53 Ϫ/Ϫ animals. These cyclin D3
Ϫ/Ϫ p53 Ϫ/Ϫ animals displayed normal tumor susceptibility and developed T cell malignancies with similar kinetics as p53 Ϫ/Ϫ mice ( Figure 5C ). Hence, cyclin D3 is dispensable for this pre-TCR-independent T cell oncogenic pathway.
It should be noted, however, that while our analyses point to a requirement for cyclin D3 in pre-TCR-dependent mouse T cell leukemias, the continued expression of cyclin D3 in these tumors may eventually become pre-TCR independent. Thus, pre-TCR signaling was shown to interfere with the activity of E2A transcription factor, via induction of an inhibitory protein, Id3 (Engel and Murre, 2001) , and this may contribute to cyclin D3 induction. On the other hand, activated Notch can also inhibit E2A activity (Ordentlich et al., 1998) , thereby mimicking some aspects of pre-TCR signaling, and this action may result in pre-TCR-independent expression of cyclin D3 in Notch-driven tumors. 
Expression of cyclin D3 in human T-ALL

A: A detailed view of the hierarchical tree of genes (rows) clustered across
The specific requirement for cyclin D3 function in murine leuke-39 T cell leukemia samples (columns) focused on the cluster of genes conmias prompted us to investigate the requirement for cyclin D3 taining cyclin D3. The normalized expression value for each gene is indiin human T cell malignancies. We decided to focus on T cell associated with cyclin D3; the association was very strong (coefficient of the log expression values ϭ 0.77). Hierarchical cluster analysis, shown in Figure 6A , illustrates the highly similar expression profiles of cyclin D3 and p56 LCK in all 39 tumors. Signifipro-T cells displayed low expression levels of the three genes cantly, among other genes within the cyclin D3 cluster, there ( Figure 6B ). are two direct targets for p56 LCK in the pre-TCR pathway, namely Comparison of absolute cyclin D3 levels with those of cyclin CD3⑀ and ZAP-70 ( Figure 6A ) (Muljo and Schlissel, 2000) . D2 revealed that leukemias corresponding to pro-T cells exAnalysis of T-ALL tumors arranged according to developpressed high levels of cyclin D2 together with low levels of cyclin mental stage (Ferrando et al., 2002) revealed that cyclin D3, D3. In contrast, more mature leukemias corresponding to prep56 LCK , and TCR␤ were highly expressed in leukemias deriving T cells and double-positive cells often expressed cyclin D3 as from later (after pre-TCR formation) stages of T cell development ( Figure 6B ). In contrast, T-ALL cases deriving from the very early a sole D-type cyclin ( Figure 6C ). This pattern very closely mirrors the expression seen by us in normal thymocyte development that this siRNA was cyclin D3 specific, i.e., it did not affect levels of cyclins D1 or D2 ( Figure 7A ). We next gauged the impact of ( Figure 3B) . Hence, the specific expression pattern of D cyclins, p56 LCK , and TCR␤, seen during lymphocyte development, is cyclin D3 knock-down on cell proliferation by comparing cell cycle distribution of cells infected with vectors encoding cyclin largely preserved in malignancies deriving from distinct developmental stages.
D3 siRNA versus cells infected with empty vectors. We found that knock-down of cyclin D3 significantly inhibited proliferation of all 12 human immature T-ALL lines ( Figure 7B , and data not Requirement for cyclin D3 in human T-ALL shown). For control, we used two T-ALL cell lines derived from Lastly, we asked whether the requirement for cyclin D3 in onco-T lymphocytes of the ␥␦ lineage and four lines derived from B genic proliferation, demonstrated by us in mouse T cell maliglymphocytes. Our analyses revealed that the proliferation of nancies, also operated in human T-ALL cells. To this end, we these six control cell lines was not significantly affected by collected 12 T-ALL cell lines (see Experimental Procedures) the knock-down of cyclin D3 ( Figure 7C , and data not shown). corresponding to immature thymocytes with rearranged TCR␤ chains, and we cultured them in vitro. We next infected the cells Collectively, these results indicate that cyclin D3 is critically required for proliferation of human T-ALL deriving from immawith retroviruses expressing siRNA against cyclin D3. Western blot analyses confirmed a significant reduction of cyclin D3 ture T cells, as an acute ablation of cyclin D3 blocks their proliferation. levels following siRNA expression ( Figure 7A ). We also verified Discussion least one D cyclin must be present to allow normal cell division. An exception to the rule is provided by the observation that While amplification of the cyclin D genes and overexpression tumor cells that lost the retinoblastoma protein no longer require of cyclin D proteins were reported in several human malignan-D cyclins, an indication that pRB is the major target for D cyclins cies, a large number of human cancers contain lesions in pathin cell cycle progression (Sherr and Roberts, 1999) . However, ways impacting on D cyclins (Ortega et al., 2002) . For this reathe dependence of cancer cells on D cyclins has not been son, elucidation of the normal functions of D cyclins is critically systematically analyzed. A recent demonstration that CDK2 acimportant to understand the role of these proteins in human tivity is dispensable in cancer cells suggests that these tumor tumorigenesis.
cells can proliferate in the absence of certain cell cycle activators In the present work, we analyzed the functions of cyclin D3 (Tetsu and McCormick, 2003) . Importantly, cyclin D-CDK4 kiby generating and studying cyclin D3-deficient mice. The very nase activity was shown to be critically required for the proliferaspecific developmental defect that we observed in cyclin D3 tion of the very same cancer cell lines (Tetsu and McCormick, null animals led us to analyze the exact molecular pathway that 2003). It should be noted that the majority of tumor cells express impinges on cyclin D3 in immature T lymphocytes. Through two or even all three D cyclins (Bartkova et al., 1998) . Since the combination of genetic crosses, in vivo studies of mice lacking three D cyclins are believed to perform overlapping, redundant particular signaling molecules (p56 LCK , TCR␤), and in vitro cell functions in cell cycle progression (Sherr and Roberts, 1999) , and molecular analyses, we determined that cyclin D3 is the one would have to target all D cyclins expressed by the tumor major downstream target of the pre-TCR→p56 LCK pathway. to arrest cancer cell proliferation. The specific requirement for cyclin D3 is restricted to this
The demonstration that a subset of T-ALL expresses cyclin particular signaling pathway, as cytokine-driven expansion of D3 as a sole D cyclin and critically depends on this cyclin for immature T cells proceeds normally in the absence of cyclin D3 proliferation offers a unique window of opportunity to use anti-( Figure 3A ). Moreover, peripheral T lymphocytes isolated from cyclin D3 therapy in selected human lymphoid malignancies. cyclin D3 null animals proliferate normally in response to TCR We propose that targeting of a single D cyclin might not be of stimulation (data not shown), again highlighting a very specific use in many human tumors that depend on multiple D cyclins requirement for cyclin D3 downstream of "pre-receptor" pre-(or do not require D cyclins at all). On the other hand, malignan-TCR signaling, but not in signaling downstream of mature TCR.
cies do exist where the driving oncogenic pathway signals to The critical role for cyclin D3 in transmitting pre-TCR-depenthe cell cycle machinery selectively via a specific D cyclin. These dent mitogenic signals prompted us to analyze the requirement malignancies need to be identified, as they represent prime for cyclin D3 in specific oncogenic pathways operating in immacandidates for anti-cyclin D therapies. Given a very narrow pheture T cells. Again, we found that cyclin D3 is essential for notype of cyclin D3-deficient mice, demonstrated here, and oncogenic pathways operating downstream of the pre-TCR, equally circumscribed impact of the loss of cyclins D1 (Fantl et while it is dispensable for a pre-TCR-independent pathway. al. Sicinski et al., 1995) or D2 (Sicinski et al., 1996) , we Specifically, we observed that mice lacking cyclin D3 are resishypothesize that agents, which cripple function of particular D tant to Notch-driven leukemias and show reduced susceptibility cyclins, might be highly selective in shutting off the proliferation to T cell malignancies triggered by p56 LCK but remain fully susof selected human malignancies, while sparing other tissues. ceptible to a pre-TCR-independent oncogenic pathway. These
We propose that human T-ALL deriving from immature T lymstudies extend our earlier, published observations that mice phocytes are good candidates for a therapeutic strategy cenlacking another component of the cell cycle machinery, cyclin tered around cyclin D3 inhibition. D1, are resistant to Ras-and Neu-driven breast cancers, while being fully susceptible to Wnt-1-and Myc-driven breast tumori- In the current study, we extended our analyses to human underwent homologous recombination at the cyclin D3 locus. Two of these clones contributed to the germline tissue when mutant mice were generated malignancies. We found that human T-ALL with rearranged using standard procedures (Sicinski et al., 1995) . For the genotyping, geno-TCR␤ chains critically require cyclin D3, as knock-down of this mic DNA was digested with Eco RI and Eco RV and analyzed by Southern protein inhibited the proliferation of tumor cells. Importantly, blotting using a 650 bp Xba I-BspE I fragment of the cyclin D3 gene (probe knock-down of cyclin D3 had no impact on proliferation of two A in Figure 1A ). Alternatively, genomic DNA was PCR amplified using cyclin T-ALL cell lines deriving from ␥␦ lineage of T cells, nor of four D3 specific primers: A (5Ј-GAACGTTGTGACGTAGGAGC-3Ј), G (5Ј-TCCAT B cell leukemias ( Figure 7C and data not shown). Collectively, CCTGCGATGGCTCAC-3Ј) and a neo gene-specific primer N3 (5Ј-TGC these results reveal a requirement for cyclin D3 function in a TGTCCATCTGCACGAGA-3Ј) by denaturing the DNA at 94ЊC for 3 min, followed by 36 cycles of amplification: 94ЊC for 1 min, 60ЊC for 1 min, 72ЊC specific subset of human lymphoid malignancies.
for 1 min, and a final extension step at 72ЊC for 7 min.
Are D cyclins good targets in human cancer therapy?
Other mouse strains and cell lines
All proliferating cells, including cancer cells, express at least Rag2 Ϫ/Ϫ mice were purchased from the Taconic Farms. Rag2 Ϫ/Ϫ or Rag2 Ϫ/Ϫ / one type of D cyclin (Bartkova et al., , 1998 cyclin D3 Ϫ/Ϫ mice were injected intraperitoneally with 100 g of anti-CD3 Tam et al., 1994; Tetsu and McCormick, 2003 Detailed information about T cell leukemia patients, RNA purification, mipackaging cell line using the Fugene 6 reagent (Roche) according to the croarray hybridization, and data acquisition have been described before manufacturer instructions. 72 hr after transfection, culture supernatants were (Ferrando et al., 2002) . Briefly, cryopreserved lymphoblast samples of 39 used to infect the J.Cam1.6 cells at the final concentration of 1 million cells/ T-ALL cases were obtained and global gene expression analysis was perml for 4 hr in the presence of Polybrene (8 g/ml). RNA was isolated and formed using Affymetrix HU6800 arrays (Ferrando et al., 2002) . processed for Northern blotting.
The p56 LCK -transformed cell lines LGF2046 and LGF10442 were derived Microarray data analysis from thymic lymphomas explanted from transgenic mice that overexpressed Data reduction was performed by filtering the expression values from Affymeconstitutively activated p56 LCK transgene (p56 LCKF505 ) driven by the p56 LCK trix HU6800 arrays using Genecluster software 2.0 (floor 100, ceiling 16,000, proximal promoter, as described (Lin and Abraham, 1997) . Cells were culfold difference Ͼ5, max-min difference Ͼ500). Data of the 452 genes that tured for 18 hr in the presence of the Src-family kinase inhibitor PP1 (Hanke passed these filters was analyzed using Cluster software (Eisen et al., 1998 (Eisen et al., ). et al., 1996 . The inhibitor was then washed off and cells were harvested at the Expression values were adjusted by performing a log transformation followed indicated time points, lysed, subjected to SDS-PAGE, and immunoblotted for by normalization and mean centering of the genes. Hierarchical clustering cyclin D3 protein.
of genes on these adjusted expression values across the 39 samples analyzed was performed using correlation (uncentered) as similarity metric, and Flow cytometry and FACS the dendrogram resulting from this analysis was visualized using Treeview. The following monoclonal antibodies were used: anti-CD3 (145-2C11), antiNearest neighbor analysis using the signal-to-noise statistics was performed CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD25 (7D4), anti-CD44 (IM7), antito identify genes associated with cyclin D3 (Golub et al., 1999) . Gene-Cluster TCR␥␦ (GL3), anti-TCR␤ (H57-597), and anti-Pan-NK cells (DX5), all from analysis software and Cluster and Treeview programs are available together PharMingen (San Diego, CA). These antibodies were directly coupled to with detailed instructions for microarray data analysis at http://wwwphycoerythtin (PE), fluorescein isothiocyanate (FITC), Cy-Chrome, or allogenome.wi.mit.edu/cancer/software/software.html and http://rana.lbl.gov/ phycocyanin (APC).
EisenSoftware.htm, respectively. To sort thymocytes into different populations, cells were first stained with biotinylated anti-CD4 and anti-CD8, followed by depletion with streptavsiRNA against cyclin D3 idin-conjugated magnetic beads (Dynal, Oslo, Norway). Depleted cells were
To target cyclin D3 expression, siRNA sequences were designed against then stained with anti-CD4-PE, anti-CD8-PE, anti-DX5-PE, anti-TCR␥␦-PE, the 5Ј-AAGGAUCUUUGUGGCCAAGGA-3Ј sequence of human cyclin D3 anti-CD44-Cy-Chrome, and anti-CD25-FITC, and PE-negative cells were transcript. Oligonucleotides were cloned into pMKO.1 retroviral vector, yieldgated and sorted. Immature single-positive cells were defined, as ing pMKO.1-␣D3. T-ALL lines (CEM, Molt 15, Molt 4, P12-Ichikawa, CD4 Ϫ CD8 ϩ TCR␤ Ϫ . Sorted cells were processed immediately for Western RPMI8402, PF382, Jurkat, HPB ALL, KE-37, CML-T1, SUP-T1, and MKB-1), or Northern blot analyses. To measure the fraction of proliferating cells, control ␥␦ T-ALL lines (Loucy and PEER), and control B cell lines (2138C, sorted thymocytes were fixed with 0.5% paraformaldehyde for 15 min on ice.
JVM2, Granta, and Daudi) were grown in 10% calf serum in RPMI, infected After fixation, cells were resuspended in a staining medium that consisted of with pMKO.1 or with pMKO.1-␣D3 retroviruses, and selected in medium 50 g/ml of propidium iodide and 250 g/ml of RNase A, then incubated containing 1-3 g/ml puromycin for 2 to 5 days, and the fraction of cells in at 37ЊC for 30 min. different phases of the cell cycle was determined by propidium iodide stainFlow cytometric analyses were done on a FACScalibur cytometer (Becking followed by FACS. Gating was done on live cells. ton Dickinson, San Jose, CA) and modeled with the MoDFit program. Cells were sorted by a MoFlo cell sorter (Cytomation, Fort Collins, CO).
